A Critical Appraisal of MAO-B Inhibitors in the Treatment of Parkinson's Disease

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2022 Feb 2

PMID 35107654

Authors

Wolfgang H Jost

Affiliations

Soon will be listed here.

Abstract

Since the 1980s, the MAO-B inhibitors have gained considerable status in the therapy of the Parkinson's disease. In addition to the symptomatic effect in mono- and combination therapies, a neuroprotective effect has repeatedly been a matter of some discussion, which has unfortunately led to a good many misunderstandings. Due to potential interactions, selegiline has declined in significance in the field. For the MAO-B inhibitor safinamide, recently introduced to the market, an additional inhibition of pathological release of glutamate has been postulated. At present, rasagiline and selegiline are being administered in early therapy as well as in combination with levodopa. Safinamide has been approved only for combination therapy with levodopa when motor fluctuations have occurred. MAO-B inhibitors are a significant therapeutic option for Parkinson's disease, an option which is too often not appreciated properly.

Citing Articles

Tailored Intranasal Albumin Caged Selegiline-α Synuclein siRNA Liposome with Improved Efficiency in Parkinson's Model.

Katamesh A, Abdel-Bar H, Break M, Hassoun S, Subaiea G, Radwan A Pharmaceutics. 2025; 17(2).

PMID: 40006609 PMC: 11859980. DOI: 10.3390/pharmaceutics17020243.

Molecular pathways: the quest for effective MAO-B inhibitors in neurodegenerative therapy.

Oyovwi M, Udi O, Atere A, Joseph G, Ogbutor U Mol Biol Rep. 2025; 52(1):240.

PMID: 39961877 DOI: 10.1007/s11033-025-10349-x.

Pelargonium graveolens Attenuates Rotenone-Induced Parkinson's Disease in a Rat Model: Role of MAO-B Inhibition and In Silico Study.

Merghany R, El-Sawi S, Naser A, Salem M, Ezzat S, Moustafa S Mol Neurobiol. 2025; .

PMID: 39921688 DOI: 10.1007/s12035-025-04727-6.

Inhibitory Activity of - and -Functionalized Monoterpene Diols Towards Monoamine Oxidases A and B.

Podturkina A, Ardashov O, Soldatova Y, Poletaeva D, Smolina A, Vasyuchenko E Int J Mol Sci. 2025; 26(1.

PMID: 39795958 PMC: 11720030. DOI: 10.3390/ijms26010097.

New class of thio/semicarbazide-based benzyloxy derivatives as selective class of monoamine oxidase-B inhibitors.

Chandran N, Lee J, Prabhakaran P, Kumar S, Sudevan S, Parambi D Sci Rep. 2024; 14(1):31292.

PMID: 39732801 PMC: 11682371. DOI: 10.1038/s41598-024-82771-3.

References

Naoi M, Maruyama W, Shamoto-Nagai M . Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease. J Neural Transm (Vienna). 2020; 127(2):131-147. DOI: 10.1007/s00702-020-02150-w. View

Cattaneo C, Barone P, Bonizzoni E, Sardina M . Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. J Parkinsons Dis. 2016; 7(1):95-101. PMC: 5302028. DOI: 10.3233/JPD-160911. View

Hudry J, Rinne J, Keranen T, Eckert L, Cochran J . Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother. 2006; 40(4):651-7. DOI: 10.1345/aph.1G454. View

Sadeghian M, Mullali G, Pocock J, Piers T, Roach A, Smith K . Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease. Neuropathol Appl Neurobiol. 2015; 42(5):423-35. DOI: 10.1111/nan.12263. View

Peretz C, Segev H, Rozani V, Gurevich T, El-Ad B, Tsamir J . Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study. Clin Neuropharmacol. 2016; 39(5):227-31. PMC: 5028154. DOI: 10.1097/WNF.0000000000000167. View

Guerra A, Suppa A, DOnofrio V, Di Stasio F, Asci F, Fabbrini G . Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease. Brain Stimul. 2019; 12(6):1517-1525. DOI: 10.1016/j.brs.2019.06.012. View

. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59(12):1937-43. DOI: 10.1001/archneur.59.12.1937. View

Larsen J, BOAS J, Erdal J . Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol. 1999; 6(5):539-47. DOI: 10.1046/j.1468-1331.1999.650539.x. View

Yahr M, Elizan T, Moros D . Selegiline in the treatment of Parkinson's disease--long term experience. Acta Neurol Scand Suppl. 1989; 126:157-61. DOI: 10.1111/j.1600-0404.1989.tb01796.x. View

10.

Schapira A, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P . Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol. 2012; 20(2):271-80. DOI: 10.1111/j.1468-1331.2012.03840.x. View

11.

Finberg J, Lamensdorf I, Commissiong J, Youdim M . Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996; 48:95-101. DOI: 10.1007/978-3-7091-7494-4_9. View

12.

Santos Garcia D, Cabo Lopez I, Labandeira Guerra C, Yanez Bana R, Cimas Hernando M, Paz Gonzalez J . Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study. Neurol Sci. 2021; 43(4):2537-2544. PMC: 8459141. DOI: 10.1007/s10072-021-05607-2. View

13.

. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993; 328(3):176-83. DOI: 10.1056/NEJM199301213280305. View

14.

. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004; 61(4):561-6. DOI: 10.1001/archneur.61.4.561. View

15.

Binda C, Hubalek F, Li M, Castagnoli N, Edmondson D, Mattevi A . Structure of the human mitochondrial monoamine oxidase B: new chemical implications for neuroprotectant drug design. Neurology. 2006; 67(7 Suppl 2):S5-7. DOI: 10.1212/wnl.67.7_suppl_2.s5. View

16.

Yelekci K, Buyukturk B, Kayrak N . In silico identification of novel and selective monoamine oxidase B inhibitors. J Neural Transm (Vienna). 2012; 120(6):853-8. DOI: 10.1007/s00702-012-0954-0. View

17.

Rascol O, Brooks D, Melamed E, Oertel W, Poewe W, Stocchi F . Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005; 365(9463):947-54. DOI: 10.1016/S0140-6736(05)71083-7. View

18.

Thorogood M, Armstrong B, Nichols T, Hollowell J . Mortality in people taking selegiline: observational study. BMJ. 1998; 317(7153):252-4. PMC: 28616. DOI: 10.1136/bmj.317.7153.252. View

19.

Pagonabarraga J, Tinazzi M, Caccia C, Jost W . The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. J Clin Neurosci. 2021; 90:178-183. DOI: 10.1016/j.jocn.2021.05.056. View

20.

Marquet A, Kupas K, Johne A, Astruc B, Patat A, Krosser S . The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther. 2012; 92(4):450-7. DOI: 10.1038/clpt.2012.128. View